Can Fite Biopharma

Can Fite Biopharma EBIT

The EBIT of Can Fite Biopharma (CANF.TA) as of Oct 17, 2026 is -10.77 M USD. In the previous year, EBIT was -8.13 M USD — a change of 32.48% (lower).

EBIT

-10.77 MUSD

YoY

32.48%

Last updated:

In 2025, Can Fite Biopharma's EBIT was -10.77 M USD, a 32.48% increase from the -8.13 M USD EBIT recorded in the previous year.

The Can Fite Biopharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2020
-14.14 M USD
Jan 1, 2021
-12.84 M USD
Jan 1, 2022
-10.10 M USD
Jan 1, 2023
-8.20 M USD
Jan 1, 2024
-8.13 M USD
Jan 1, 2025
-10.77 M USD
Jan 1, 2026 (e)
-337.89 M USD
Jan 1, 2027 (e)
12.88 B USD
The Can Fite Biopharma EBIT history
YEAREBITYoY
est12.88 BUSD-3,911.90%
est-337.89 MUSD+3,037.15%
-10.77 MUSD+32.48%
-8.13 MUSD-0.79%
-8.20 MUSD-18.83%
-10.10 MUSD-21.38%
-12.84 MUSD-9.17%
-14.14 MUSD+17.76%
-12.01 MUSD+121.78%
-5.41 MUSD-26.60%
-7.38 MUSD-14.57%
-8.63 MUSD+34.59%
-6.42 MUSD+174.48%
-2.34 MUSD-20.67%
-2.95 MUSD+50.03%
-1.96 MUSD+25.49%
-1.56 MUSD+26.89%
-1.23 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Can Fite Biopharma Revenue

Can Fite Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
763,000.00 USD
-14.14 M USD
-14.44 M USD
Jan 1, 2021
853,000.00 USD
-12.84 M USD
-12.60 M USD
Jan 1, 2022
810,000.00 USD
-10.10 M USD
-10.17 M USD
Jan 1, 2023
743,000.00 USD
-8.20 M USD
-7.63 M USD
Jan 1, 2024
674,000.00 USD
-8.13 M USD
-7.88 M USD
Jan 1, 2025
438,400.00 USD
-10.77 M USD
-10.64 M USD
Jan 1, 2026 (e)
404,000.00 USD
-337.89 M USD
-7,099.15 USD
Jan 1, 2027 (e)
404,000.00 USD
12.88 B USD
-1,774.20 USD

Can Fite Biopharma Margins

Can Fite Biopharma stock margins

The Can Fite Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Can Fite Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Can Fite Biopharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
100.00 %
-1,853.08 %
-1,892.92 %
Jan 1, 2021
100.00 %
-1,505.51 %
-1,476.55 %
Jan 1, 2022
100.00 %
-1,246.42 %
-1,255.93 %
Jan 1, 2023
100.00 %
-1,102.96 %
-1,027.46 %
Jan 1, 2024
100.00 %
-1,206.23 %
-1,169.14 %
Jan 1, 2025
94.07 %
-2,456.79 %
-2,426.67 %
Jan 1, 2026 (e)
94.07 %
-83,635.90 %
-1.76 %
Jan 1, 2027 (e)
94.07 %
3.19 M %
-0.44 %

Can Fite Biopharma Stock analysis

What does Can Fite Biopharma do? Can-Fite Biopharma Ltd. is an Israeli company specializing in the development of drugs for inflammatory diseases and cancer. It was founded in 1994 by Prof. Pnina Fishman and is headquartered in Petach Tikva, Israel. The company initially focused on studying the function of adenosine receptors in central nervous system diseases, but later expanded to develop drugs for inflammatory diseases and cancer. Can-Fite went public in 2007 and has been able to finance its research projects through investors and partnerships. The company's business model revolves around developing an innovative portfolio of drugs for immune system disorders and cancer by targeting adenosine receptors. It aims to expand its drug pipeline to successfully treat a wide range of diseases. Can-Fite's drug pipeline is divided into different areas, including inflammatory diseases, cancer, and ophthalmology. The company has already brought several drugs to market or is in the clinical testing phase, including CF101 for rheumatoid arthritis and psoriasis, Namodenoson for liver cancer, and Piclidenoson for autoimmune diseases. Overall, Can-Fite Biopharma Ltd. is a promising company focused on developing innovative drugs for inflammatory diseases and cancer. Can Fite Biopharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Can Fite Biopharma's EBIT

Can Fite Biopharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Can Fite Biopharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Can Fite Biopharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Can Fite Biopharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Can Fite Biopharma stock

EBIT of Can Fite Biopharma is -10.77 M USD in 2025.

EBIT of Can Fite Biopharma changed from -8.13 M USD to -10.77 M USD, representing a 32.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Can Fite Biopharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Can Fite Biopharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Can Fite Biopharma

All Key Metrics — Can Fite Biopharma